Alistair Milnes
CIK: 0001901321
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (15 total)
- Jun 24, 2026FEMY
FEMASYS INC
Award(A)DirectStock Option (Right to Buy)
880 shares- - Jan 5, 2026BCYC
BICYCLE THERAPEUTICS PLC
Sale(S)Direct3.4K shares at avg. $6.46$22K - Jan 2, 2026BCYC
BICYCLE THERAPEUTICS PLC
Award(A)Direct50K shares- - Jan 2, 2026BCYC
BICYCLE THERAPEUTICS PLC
Sale(S)Direct3.2K shares at avg. $6.80$22K - Oct 3, 2025BCYC
BICYCLE THERAPEUTICS PLC
Sale(S)Direct978 shares at avg. $8.41$8K - Oct 2, 2025BCYC
BICYCLE THERAPEUTICS PLC
Sale(S)Direct1.1K shares at avg. $8.40$10K - Jul 3, 2025BCYC
BICYCLE THERAPEUTICS PLC
Sale(S)Direct966 shares at avg. $7.44$7K - Jul 2, 2025BCYC
BICYCLE THERAPEUTICS PLC
Sale(S)Direct1.1K shares at avg. $7.09$8K - Jun 25, 2025FEMY
FEMASYS INC
Award(A)DirectStock Option (Right to Buy)
17.6K shares- - Apr 3, 2025BCYC
BICYCLE THERAPEUTICS PLC
Sale(S)Direct1K shares at avg. $7.48$8K - Apr 2, 2025BCYC
BICYCLE THERAPEUTICS PLC
Sale(S)Direct1.1K shares at avg. $8.02$9K - Jan 3, 2025BCYC
BICYCLE THERAPEUTICS PLC
Sale(S)Direct936 shares at avg. $14.75$14K - Jan 2, 2025BCYC
BICYCLE THERAPEUTICS PLC
Sale(S)Direct4.6K shares at avg. $14.09$65K - Jan 2, 2025BCYC
BICYCLE THERAPEUTICS PLC
Award(A)Direct35K shares- - Oct 3, 2024BCYC
BICYCLE THERAPEUTICS PLC
Sale(S)Direct972 shares at avg. $22.26$22K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 24, 2026 |  FEMY FEMASYS INC | Award(A) Stock Option (Right to Buy) | 880 | - | - | Direct |
| Jan 5, 2026 |  BCYC BICYCLE THERAPEUTICS PLC | Sale(S) | 3,416 | $6.46 | $22,067 | Direct |
| Jan 2, 2026 | BCYC BICYCLE THERAPEUTICS PLC | Award(A) | 50,000 | - | $0 | Direct |
| Jan 2, 2026 | BCYC BICYCLE THERAPEUTICS PLC | Sale(S) | 3,244 | $6.80 | $22,059 | Direct |
| Oct 3, 2025 | BCYC BICYCLE THERAPEUTICS PLC | Sale(S) | 978 | $8.41 | $8,225 | Direct |
| Oct 2, 2025 | BCYC BICYCLE THERAPEUTICS PLC | Sale(S) | 1,147 | $8.40 | $9,635 | Direct |
| Jul 3, 2025 | BCYC BICYCLE THERAPEUTICS PLC | Sale(S) | 966 | $7.44 | $7,187 | Direct |
| Jul 2, 2025 | BCYC BICYCLE THERAPEUTICS PLC | Sale(S) | 1,149 | $7.09 | $8,146 | Direct |
| Jun 25, 2025 | FEMY FEMASYS INC | Award(A) Stock Option (Right to Buy) | 17,600 | - | - | Direct |
| Apr 3, 2025 | BCYC BICYCLE THERAPEUTICS PLC | Sale(S) | 1,038 | $7.48 | $7,764 | Direct |
| Apr 2, 2025 | BCYC BICYCLE THERAPEUTICS PLC | Sale(S) | 1,133 | $8.02 | $9,087 | Direct |
| Jan 3, 2025 | BCYC BICYCLE THERAPEUTICS PLC | Sale(S) | 936 | $14.75 | $13,806 | Direct |
| Jan 2, 2025 | BCYC BICYCLE THERAPEUTICS PLC | Sale(S) | 4,578 | $14.09 | $64,504 | Direct |
| Jan 2, 2025 | BCYC BICYCLE THERAPEUTICS PLC | Award(A) | 35,000 | - | $0 | Direct |
| Oct 3, 2024 | BCYC BICYCLE THERAPEUTICS PLC | Sale(S) | 972 | $22.26 | $21,637 | Direct |
1-15 of 15 transactions
About Milnes Alistair
Milnes Alistair (SEC CIK 0001901321) files insider reports with the SEC as Director of FEMASYS INC (FEMY) and CHIEF OPERATING OFFICER of BICYCLE THERAPEUTICS PLC (BCYC).
Signal8 holds 8 ownership filings by Milnes Alistair, all Form 4s, filed between Oct 4, 2024 and Aug 11, 2026. Those filings report 15 transactions, from Oct 3, 2024 to Jun 24, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Milnes Alistair's filings is in SUWANEE, GA.
Recent filings by Milnes Alistair
- Jun 24, 2026: Grant or award of FEMY derivative securities (Form 4, code A).
- Jan 5, 2026: Open-market sale of BCYC shares (Form 4, code S).
- Jan 2, 2026: Grant or award of BCYC shares (Form 4, code A).
- Jan 2, 2026: Open-market sale of BCYC shares (Form 4, code S).
- Oct 3, 2025: Open-market sale of BCYC shares (Form 4, code S).
Other insiders filing for FEMASYS INC (FEMY)
- Eichenbaum Kenneth D., Director
- Uzialko Edward R, Director
- Larsen Charles, Director
- Mifek Jeffrey Gerald, Chief Clinical-Medical Affairs
- Sipos Jeremy Alexander, Chief Technology Officer
- Canning John Charles, Chief Operating Officer